MOUD Buprenorphine Subli denied as experimental or investigational by Centene?

Mirrors state Medicaid PDLs. Most state Medicaid programs (post-2023 X-waiver removal) allow PCP prescribing without specialist gatekeeping.

MATA Act 2022 / DATA 2000 X-waiver removal — any DEA-registered prescriber may prescribe buprenorphine. ASAM NPG OUD 2020 first-line. SAMHSA TIP 63 supports doses >24 mg for fentanyl-era patients. EPSDT for under-21.

## Why Centene Issued This Denial

A denial of sublingual buprenorphine for MOUD as "experimental" or "investigational" is factually difficult to sustain — sublingual buprenorphine has been FDA-approved for opioid dependence treatment for well over a decade and is endorsed as a first-line evidence-based treatment by major federal health agencies including SAMHSA and by leading addiction medicine and psychiatric professional organizations. This denial should be appealed immediately.

The most likely explanation is a system or coding error: the wrong product code was submitted, the claim was filed under a general "buprenorphine" code that maps to an unapproved formulation or indication, or a clinical review was triggered that applied the wrong coverage policy. Less commonly, Centene's reviewer may have applied an outdated policy.

## Why This Denial Is Appealable

An "experimental" denial is overturned when documentation demonstrates that the medication is FDA-approved for the specific indication being treated and is consistent with generally accepted medical practice as reflected in recognized clinical guidelines. Federal anti-discrimination rules under MHPAEA further prohibit singling out MOUD for coverage barriers that exceed those applied to other chronic disease treatments.

## Federal Appeal Framework

• Internal appeal (Level 1): File within the deadline on the denial letter. Centene must respond within 30 days (standard) or 72 hours (expedited).
• External review (ACA §2719 / ERISA §503): Available after exhausting internal appeals — generally within four months of the final internal denial. An IRO independently assesses whether the treatment meets the generally accepted medical practice standard.
• Expedited review: Available when delay would seriously jeopardize health — MOUD discontinuation can carry significant clinical risk, which supports an expedited request.

## Concrete Appeal Steps

1. Obtain Centene's definition of "experimental/investigational" from their coverage policy — most require that a treatment lack FDA approval or established clinical evidence. 2. Pull the FDA prescribing label for the specific sublingual buprenorphine product, confirming its approval for opioid use disorder treatment. 3. Reference Centene's own clinical policy (if available) as well as SAMHSA's Treatment Improvement Protocol and applicable addiction medicine society guidelines to document that buprenorphine MOUD is standard of care. 4. Have the prescriber write a letter citing these sources and confirming the treatment is consistent with generally accepted standards. 5. Include the diagnosis confirmation and clinical rationale for this specific patient. 6. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• FDA prescribing label confirming approval for opioid use disorder
• Prescriber's letter addressing the experimental-denial criteria and citing established guideline endorsement (e.g., SAMHSA, relevant specialty society)
• Diagnosis confirmation for opioid use disorder
• Any Centene clinical coverage policy language defining "experimental"
• Clinical chart notes supporting the treatment decision

## Criteria-Mapping Structure

| Centene "Experimental" Criterion | Supporting Evidence | |---|---| | FDA-approved for the indication | FDA label for the specific product + indication | | Consistent with generally accepted medical practice | SAMHSA guidance + specialty-society endorsement cited in prescriber letter | | Not limited to investigational use only | FDA approval documentation |